Shionogi & Co., Ltd. · TSE:4507
Shionogi & — Q3 FY2025 Earnings Presentation
34 slides from Shionogi &'s earnings presentation, Jan 30, 2026
Slide 1: 3rd Quarter of Fiscal 2025 Financial Results
3rd Quarter of Fiscal 2025 Financial Results January 30, 2026 Shionogi & Co., Ltd. 1
Slide 2: Agenda
Agenda 01 Overview of Q3 FY2025 Financial Results （P.3-9） 02 Toward the Realization of the 2030 Vision （P.10-23） • Business Investment Progress • Development Pipeline Progress 2
Slide 3: Overview of Q3 FY2025 Financial Results
Overview of Q3 FY2025 Financial Results 3
Slide 4: Highlights of the Third Quarter
Highlights of the Third Quarter Revenue, operating profit, and profit attributable to owners of the parent for the cumulative third quarter reached record highs - As a one-off factor boosting profit, a gain on negative goodwill gain associated with the acquisition of JT Group’s pharmaceutical busi
Slide 5: Financial Results
Financial Results Revenue and all profit items increased year-on-year, showing steady progress toward achieving the full-year forecast (Unit: B yen) FY2025 FY2024 Y on Y Forecasts Apr.-Dec. Achievement Apr.-Dec. Change (%) Change Full year Results (%) Results Revenue 500.0 360.7 72.1 333.6 8.1 27.1
Slide 6: Statement of Profit or Loss
Statement of Profit or Loss (Unit：B yen) FY2025 FY2024 Y on Y Main variation factors (Y on Y) Forecasts Achievem Apr.-Dec. Apr.-Dec. Change Full year Results ent Results (%) Change Revenue (%) Increase: Prescription drugs, Royalty income, Revenue 500.0 360.7 72.1 333.6 8.1 27.1 Overseas subsidiaries
Slide 7: Revenue by Segment
Revenue by Segment (Unit：B yen) FY2025 FY2024 Y on Y Main variation factors (Y on Y) Forecast Apr.-Dec. Achieveme Apr.-Dec. Change nt(%) Change Full year Results Results (%) Prescription drugs Prescription drugs 143.5 86.7 60.4 78.9 9.8 7.8 Overseas Increase: Sales of TORII subsidiaries/export 61.0
Slide 8: Prescription Drugs in Japan
Prescription Drugs in Japan （Unit: B yen) FY2025 FY2024 Y on Y Forecast Apr.-Dec. Achievement Apr.-Dec. Change(%) Change Full year Results (%) Results Acute Respiratory Virus Infection 56.0 27.3 48.7 43.3 (37.0) (16.0) Treatments Quviviq 2.5 1.1 44.3 0.5 123.8 0.6 Symproic 6.5 4.6 70.5 3.8 18.8 0.7
Slide 9: Results for the Third Quarter
Results for the Third Quarter Growth in core businesses led to record-high sales revenue, operating profit, and quarterly profit attributable to owners of the parent company Stable performance in HIV and • Strong growth of LAI*1 products overseas businesses • Steady growth of cefiderocol in the U.S.
Slide 10: Toward the Realization of the 2030 Vision
Toward the Realization of the 2030 Vision • Business Investment Progress • Development Pipeline Progress 10
Slide 11: Business Investments Executed in FY2025
Business Investments Executed in FY2025 Active investing in business to realize the 2030 Vision Executed a diverse range of strategic business investments Additional investment in ViiV M&A involving JT Group’s Acquisition of the edaravone pharmaceutical business business Purpose: Purpose: Purpose: •
Slide 12: SHIONOGI's Growth Driven by HIV Business
SHIONOGI’s Growth Driven by HIV Business Multiple integrase inhibitors discovered by SHIONOGI have significantly contributed to growth Sales Trend on SHIONOGI FY2014~ 500 Dolutegravir has provided a stable foundation for SHIONOGI’s growth 400 FY2021~ 300 Others Accelerated growth from increased B ye
Slide 13: Long-acting Injectables Driving a Paradigm Shift in the HIV Market
Long-acting Injectables Driving a Paradigm Shift in the HIV Market Addressing unmet needs through innovative solutions to achieve sustained growth 2021~: Formulation administered once every month 2022~: Formulation administered once every two months - From 2028 to 2030: Formulation administered once
Slide 14: Partnership with ViiV Healthcare
Partnership with ViiV Healthcare Strengthening partnership with ViiV Healthcare to ensure a stable earnings base and drive further growth ーChanges in shareholding ratioー 1 Establishment of ViiV Healthcare (by GSK and Pfizer) 1 2 3 Revision of contractual framework 100 2 with ViiV Healthcare 80 Tra
Slide 15: Integration of JT's Pharmaceutical Business
Strengthening our in-house discovery capabilities Integration of JT’s Pharmaceutical Business A new research and development framework has been launched to create innovative pharmaceuticals and deliver them globally Acquired drug discovery M&A background platform Strategic goals Approximately 670 re
Slide 16: Integration with TORII
Integration with TORII Enhancing domestic sales by leveraging sales synergies and expanding our product lineup to meet market needs - Strengthening domestic sales - ① 営業活動のシナジー効果 -Strengthening business that does not rely on patents- Shionogi -Sublingual immunotherapy (SLIT)- Focus Areas Infectious
Slide 17: Overview of the Edaravone Business Acquisition
Overview of the Edaravone Business Acquisition Acquiring full rights to edaravone and a U.S. commercial platform to accelerate global growth beyond infectious disease areas ーPurpose of the business acquisitionー ーTransaction overviewー • Acquisition Target: All global rights to edaravone Expand our U.
Slide 18: Innovative Therapeutic Drugs Addressing Unmet Needs
Innovative Therapeutic Drugs Addressing Unmet Needs A marketed product with established safety and efficacy, expected to deliver stable growth going forward ーFeatures of edaravoneー ーU.S. Sales trend of edaravone (Radicava)*1ー • Indication: Treatment of amyotrophic lateral 700 sclerosis (ALS) 600 Inj
Slide 19: Toward Establishing a Rare Disease Business in the U.S.
Toward Establishing a Rare Disease Business in the U.S. Acquire a strong business foundation for expansion in the rare disease field ーBusiness foundations to be acquiredー ーExpansion of our U.S. business over the mid- to long-termー Build a commercial infrastructure in anticipation of 1 rare disease p
Slide 20: Positioning of Business Investments within the Corporate Strategy
Positioning of Business Investments within the Corporate Strategy*1 We are making investments to strengthen SHIONOGI’s foundation toward achieving the 2030 Vision Sale by our own business Areas to strengthen: Sale of pharmaceuticals Areas to strengthen: A non-patent-dependent products and services t
Slide 21: Toward the Realization of the 2030 Vision
Toward the Realization of the 2030 Vision • Business Investment Progress • Development Pipeline Progress 21
Slide 22: Major Development Projects: Infectious Diseases
Major Development Projects: Infectious Diseases Project Indication Current stage*1 Update COVID-19 treatment Submission COVID-19 treatment (age 6-11) Submission Ensitrelvir COVID-19 PEP Submission COVID-19 treatment (age 0-5) Phase 3 FPI*3 achieved S-268024 COVID-19 (JN.1 vaccine) Submission Submitt
Slide 23: Major Development Projects: QOL Diseases with High Social Impact
Major Development Projects: QOL Diseases with High Social Impact Project Indication Current stage*1 Update Zuranolone Depression Approved Approved in Japan Resiniferatoxin Pain associated with knee osteoarthritis Phase 3 Fragile X syndrome Phase 2/3 Zatolmilast Jordan syndrome Phase 2 LPI achieved D
Slide 24: Appendix
Appendix 24 @® snionoai
Slide 25: FY2025 Exchange Rate
FY2025 Exchange Rate Exchange rate (average during the period) FY2025 Forecast Apr.-Dec. Results （10/27） USD($) – JPY(¥) 146 yen 148.71 yen GBP(£) – JPY(¥) 197 yen 198.98 yen EUR(€) – JPY(¥) 171 yen 171.84 yen 25
Slide 26: Major Development Products
Major Development Products - Infectious Diseases - - QOL Diseases - Target Launch Target Launch Pipeline Indication Current stage Timing*1 Pipeline Indication Current stage Timing*1 COVID-19 treatment Submission - FY2027 Zuranolone Depression Approved FY2025 Pain associated with Ensitrelvir Resinife
Slide 27: R&D Milestones Planned for FY2025
R&D Milestones Planned for FY2025 Red: Update from October 28, 2025, to January 30, 2026, : Milestone-completed items ※Topline results: It is the timing of acquisition, and the timing of disclosure will be considered separately Disease area Pipeline Indication Current stage FY2025 1H FY2025 2H COVID
Slide 28: Pipeline: Infectious Diseases
Pipeline: Infectious Diseases as of January 30, 2026 Preclinical Phase 1 Phase 2 Phase 3 Submission 2025年1月31日現在 S-872600 S-743229 S-337395 Cefiderocol Ensitrelvir Cefiderocol AMR (Complicated urinary Gram-negative bacterial AMR (Gram-negative Influenza nasal vaccine RSV infections COVID-19 treatmen
Slide 29: Pipeline: QOL Diseases with High Social Impact
Pipeline: QOL Diseases with High Social Impact as of January 30, 2026 Preclinical Phase 1 Phase 2 S-540956 S-151128 S-261261(JTV-261)*1 S-309309 Redasemtide Zatolmilast Nucleic acid adjuvan Chronic pain Thrombosis Obesity Acute ischemic stroke Jordan syndrome S-109802 S-588210 S-662662(JTT-662)*1 S-
Slide 30: Pipeline: QOL Diseases with High Social Impact
Pipeline: QOL Diseases with High Social Impact as of January 30, 2026 Phase 3 Submission Resiniferatoxin [GRT7039] SR-0379 Tapinarof Naldemedine Tapinarof Pain associated with knee Cutaneous ulcer Atopic dermatitis in infants Opioid-induced Constipation Atopic dermatitisin Pediatric Patients osteoar
Slide 31: Anti-HIV Drug Released by ViiV
Anti-HIV Drug Released by ViiV Product CY2024 Formulations Compounds*1 Administrations Frequency Indications name Sales Cabenuva CAB＋RPV IM injection Q2M (LA) Treatment ￡1,013M LAI formulations Apretude CAB IM injection Q2M (LA) PrEP*2 ￡279M Dovato DTG＋3TC Oral Every day Treatment ￡2,239M Oral two-d
Slide 32: Growth Outlook for the HIV Market (Treatment + Prevention)
Existing 新製品・ businesses Growth Outlook for the HIV Market (Treatment + Prevention) 新規事業 In the treatment and PrEP market, LA formulations will continue to drive growth Treatment Outlook for the HIV Market*1 (Treatment + PrEP) • In the US, new infections have increased by approximately 2.5-3% in rec
Slide 33: Other Major progress
Other Major progress*1 • November − Shionogi Pharma’s Kanegasaki Plant Receives “BSI Kitemark for Minimized Risk of AMR” Certification for Antimicrobial Manufacturing − New Clinical Data on the Efficacy of Antiviral Treatments for Post-COVID-19 Condition − Launched XOFLUZA® Granules 2% – New Formula
Slide 34: Forward-Looking Statements
Forward-Looking Statements • Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclos